文献速递药物相互作用

强CYP3A诱导剂卡马西平对zongertinib药代动力学的影响

The effect of carbamazepine, a strong CYP3A inducer, on the pharmacokinetics of zongertinib in healthy male volunteers.
PubMed 文献 · Pharmacotherapy · 2024-12-27

本研究在健康男性志愿者中开展开放标签、两周期、固定序列的药物相互作用试验,评估多剂量口服卡马西平对单次口服60 mg zongertinib药代动力学的影响。结果显示,卡马西平使zongertinib的AUC0-∞和AUC0-tz均降至36.5%,Cmax降至56.4%,提示zongertinib暴露量降低63.5%。

要点

  • 卡马西平使zongertinib的AUC0-∞和AUC0-tz均降至36.5%(90%CI分别为32.0%-41.6%和31.9%-41.7%)。
  • 卡马西平使zongertinib的Cmax降至56.4%(90%CI:45.1%-70.6%)。
  • 与强CYP3A诱导剂合用时应关注zongertinib暴露量显著降低的临床风险。

核心结论

  • zongertinib与强CYP3A诱导剂卡马西平合用时,其暴露量降低63.5%。

研究设计与样本

  • 开放标签、两周期、固定序列的临床药物相互作用研究。

主要发现

  • 合用卡马西平后,zongertinib的AUC0-∞降至单用时的36.5%(90%CI:32.0%-41.6%)。
  • 合用卡马西平后,zongertinib的AUC0-tz降至单用时的36.5%(90%CI:31.9%-41.7%)。
  • 合用卡马西平后,zongertinib的Cmax降至单用时的56.4%(90%CI:45.1%-70.6%)。

临床怎么用

  • 临床上应避免zongertinib与强CYP3A诱导剂(如卡马西平)合用,以防暴露量显著降低影响疗效。

局限性

  • 研究仅纳入健康白人男性受试者,结果外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Zongertinib (BI 1810631) is a potent, selective, and epidermal growth factor receptor (EGFR) wild-type sparing human epidermal growth factor receptor 2 (HER2) inhibitor. Based on in vitro data, the oxidative hepatic metabolism of zongertinib is principally driven by cytochrome P450 (CYP) 3A4/5. Therefore, zongertinib may be affected by strong CYP3A inducers, like carbamazepine. OBJECTIVE: This study aimed to investigate the effect of multiple oral doses of carbamazepine on the pharmacokinetics of a single oral dose of zongertinib in healthy male subjects. METHODS: This open-label, two-period, fixed-sequence clinical drug-drug interaction study examined the pharmacokinetics of a single 60-mg oral dose of zongertinib in the absence or presence of multiple oral doses of carbamazepine. The extent of drug-drug interaction was estimated using the adjusted geometric mean ratios (and 90% confidence intervals [CIs]) for the test treatment (zongertinib in the presence of carbamazepine) versus the reference treatment (zongertinib alone) for areas under the plasma concentration-time curve from time 0 to infinity and to the last quantifiable time point (AUC0-∞, AUC0-tz) and maximum measured plasma concentration (Cmax). RESULTS: Sixteen subjects (all Caucasian males) received zongertinib alone in Study Period 1, and 15 of them received both zongertinib and carbamazepine in Study Period 2. Upon co-administration with carbamazepine in Study Period 2, AUC0-∞ and AUC0-tz of zongertinib were both reduced to 36.5% (90% CI: 32.0%-41.6% for AUC0-∞ and 31.9%-41.7% for AUC0-tz). The Cmax of zongertinib was reduced to 56.4% (90% CI: 45.1%-70.6%). CONCLUSION: Zongertinib exposure was reduced by 63.5% when coadministered with the strong CYP3A inducer, carbamazepine.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Tian X, Esmaeili H, Minich D, et al. The effect of carbamazepine, a strong CYP3A inducer, on the pharmacokinetics of zongertinib in healthy male volunteers. Pharmacotherapy. 2024. PMID: 39727284. doi:10.1002/phar.4641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。